埃达拉对抗慢性热应激暴露的脏保护作用
Laiali T Alquraan1, Karem H Alzoubi2,3, Sanaa Jaber4
1Department of Biological Sciences, The Faculty of Science, Yarmouk University, Irbid, Jordan.
Naunyn-Schmiedeberg's archives of pharmacology
|December 3, 2024
概括
埃达拉 (EDV) 通过减少氧化应激和炎症,保护大鼠免受热应激诱导的损伤. 这种抗氧化和抗炎剂使关键生物标志物正常化,改善了脏组织的健康.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 热应激是一个重要的环境挑战,可以导致器官损伤,包括脏损伤.
- 氧化应激和炎症是热应激引起的损伤的关键机制.
- 埃达拉 (EDV) 是一种强大的抗氧化剂和抗炎剂,在各种疾病中显示出治疗潜力.
研究的目的:
- 在热应激诱导损伤的小鼠模型中研究埃达拉 (EDV) 的保护作用.
- 评估EDV对氧化应激标志物,炎症细胞因子和热应激后组织学的影响.
主要方法:
- 在治疗组中,雄性Wistar大鼠接受了8周的热应激,同时服用埃达拉 (6mg/kg).
- 测量血清肌素和尿素水平以评估功能.
- 分析了脏氧化应激标志物 (甲,触酶活性) 和炎症性细胞因子mRNA表达 (TNF-α,IL-1β).
- 进行了组织病理学检查的脏组织.
主要成果:
- 热应激显著增加了血清肌素和尿素,增加了脏甲基和酶活性,并提高了TNF-α和IL-1βmRNA表达的调节.
- 与热应激组相比,埃达拉治疗显著降低了血清肌素和尿素水平.
- EDV使脏氧化应激生物标志物正常化,并显著降低了炎症性细胞因子的表达.
- 组织病理学分析显示,用Edaravone治疗的老鼠的脏组织损伤减少.
结论:
- 埃达拉在老鼠中表现出显著的保护作用,防止热应激诱导的损伤.
- 这些保护作用归因于Edaravone强大的抗氧化和抗炎性质.
- 埃达拉作为缓解热应激相关损伤的治疗剂具有前景.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
01:25Antihypertensive Drugs: Direct Renin Inhibitors
490
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
490
01:22Heart Failure Drugs: Diuretics
340
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
340
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
477
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
477
01:11Renal Failure: Dose Adjustments
63
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
63
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
581
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
581